0.05Open0.05Pre Close0 Volume3.35K Open Interest1.50Strike Price0.00Turnover234.67%IV29.27%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1296Delta0.3177Gamma41.00Leverage Ratio-0.0101Theta-0.0001Rho-5.31Eff Leverage0.0006Vega
Sangamo Therapeutics Stock Discussion
Fabry gene therapy has almost no side effects and requires no steroids or immunosuppressive therapy at all so far.
This is rare in gene therapy.
Pfizer presents P3 data at ASH next week December 9th
And Fabry deal discussions are well underway after getting Acellerated Approval from FDA recently. A couple of nice near term catalysts that should move the stock.
📊⚡️📊
No comment yet